MCID: CRY003
MIFTS: 54

Cryptosporidiosis

Categories: Gastrointestinal diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Cryptosporidiosis

MalaCards integrated aliases for Cryptosporidiosis:

Name: Cryptosporidiosis 12 74 52 58 54 42 3 43 15 71 32
Cryptosporidial Gastroenteritis 12 71
Infection by Cryptosporidium 12
Intestinal Cryptosporidiosis 12

Characteristics:

Orphanet epidemiological data:

58
cryptosporidiosis
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Cryptosporidiosis

MedlinePlus : 42 Cryptosporidiosis (crypto) is an illness caused by a parasite. The parasite lives in soil, food, and water. It may also be on surfaces that have been contaminated with feces (poop). You can become infected by swallowing the parasite, if it is in your food, drinking water, or water that you swim in. You can also get it by touching your mouth with contaminated hands. The most common symptom of crypto is watery diarrhea. Other symptoms include Dehydration Weight loss Stomach cramps or pain Fever Nausea Vomiting Contact your health care provider if you have watery diarrhea that lasts more than a few days. Most people with crypto get better without treatment within one to two weeks. But crypto can cause serious problems in people with weak immune systems, like those with HIV/AIDS. To reduce your risk of crypto, wash your hands often, only drink water that you know is safe, and wash or peel fresh fruits and vegetables before eating. Centers for Disease Control and Prevention

MalaCards based summary : Cryptosporidiosis, also known as cryptosporidial gastroenteritis, is related to diarrhea and gastroenteritis, and has symptoms including fever and pruritus. An important gene associated with Cryptosporidiosis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Allograft rejection and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Azithromycin and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, small intestine and t cells, and related phenotypes are immunodeficiency and decreased proportion of cd4-positive t cells

Disease Ontology : 12 A coccidiosis that involves a parasitic protozoan infection of the intestine of humans and a wide range of animals caused by Cryptosporidium species, through contaminated water and food, The symptoms include watery diarrhea, dehydration, weight loss, abdominal pain, fever, nausea and vomiting. Cryptosporidium infections have also been found in other digestive tract organs, the lungs, and conjunctiva. Immunocompromised persons are at greater risk of developing the infection.

NIH Rare Diseases : 52 Cryptosporidiosis is an illness caused by the parasite, Cryptosporidium. The condition is most commonly associated with watery diarrhea. Other signs and symptoms may include dehydration, weight loss, stomach cramps, fever, nausea and/or vomiting. Cryptosporidiosis occurs when the parasite enters the body, often through contaminated food and water or because of poor handwashing hygiene. Although cryptosporidiosis can affect all people, young children, pregnant women and people with severely weakened immune systems (i.e. those with AIDS; cancer and transplant patients who are taking certain immunosuppressive drugs; and those with inherited diseases that affect the immune system ) are likely to develop a more serious illness. Medications such as nitazoxanide have been used to treat diarrhea in both adults and children. However, most people who have healthy immune systems will recover without treatment.

CDC : 3 Many species and genotypes of the apicomplexan protozoan Cryptosporidium can infect humans and have a wide range of host animals. Zoonotic species and genotypes of Cryptosporidium are those transmitted from animal hosts to humans, and non-zoonotic species and genotypes are host-adapted without evidence of transmission from animals to humans. Cryptosporidium parvum (formerly known as C. parvum genotype II) and C. hominis (formerly known as C. parvum genotype I) are the leading causes of human cryptosporidiosis. C. meleagridis, C. felis, C. canis, C. ubiquitum, C. cuniculus, C. viatorum, Chipmunk genotype I, Cryptosporidium mink genotype, and C. muris can also infect humans.

Wikipedia : 74 Cryptosporidiosis, also known as crypto, is a parasitic disease caused by Cryptosporidium, a genus of... more...

Related Diseases for Cryptosporidiosis

Diseases related to Cryptosporidiosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 405)
# Related Disease Score Top Affiliating Genes
1 diarrhea 32.2 TAC1 SST CSF3 CD40LG
2 gastroenteritis 31.4 CSF3 CCL11 CAT
3 toxoplasmosis 31.0 DHFR CD79A CD40LG
4 immune deficiency disease 31.0 MBL2 CXCL10 CD79A CD40LG CD4
5 dysentery 30.7 IL1A CD40LG CD4
6 bronchiolitis 30.7 CXCL10 CD40LG CCL11
7 amebiasis 30.7 CD79A CD40LG CD4
8 cyclosporiasis 30.6 TPI1 CD4
9 combined t cell and b cell immunodeficiency 30.6 CD8A CD40LG CD4
10 irritable bowel syndrome 30.3 VIP TAC1 SST
11 respiratory failure 30.3 TAC1 CXCL10 CD4 CCL11 CAT
12 pyelonephritis 30.3 MBL2 CXCL10 CSF3
13 proteasome-associated autoinflammatory syndrome 1 30.3 IL1A CXCL10 CCL11
14 chlamydia 30.2 MBL2 CD79A CD40LG
15 constipation 30.2 VIP TAC1 SST CAT
16 strongyloidiasis 30.1 CD79A CD40LG CD4 CCL11
17 bronchitis 30.1 VIP TAC1 CXCL10 CD40LG CCL11 CAT
18 giardiasis 30.1 TPI1 CD8A CD79A CD40LG CD4 CACNA1B
19 leprosy 3 30.0 CXCL10 CD8A CD40LG CD4
20 duodenitis 30.0 CD8A CD40LG CD4
21 bronchopneumonia 30.0 CD8A CD40LG CD4
22 poliomyelitis 30.0 CD8A CD40LG CD4
23 chickenpox 30.0 CD8A CD40LG CD4
24 thrombocytopenia 29.9 IL1A CXCL10 CSF3 CD79A CD40LG
25 pneumocystosis 29.9 DHFR CSF3 CD8A CD40LG CD4
26 oral candidiasis 29.9 IL1A CD8A CD4
27 listeriosis 29.8 MBL2 CD8A CD4
28 human immunodeficiency virus infectious disease 29.8 MBL2 CD8A CD79A CD4
29 exanthem 29.8 CSF3 CD8A CD40LG CD4
30 parasitic helminthiasis infectious disease 29.8 CD8A CD40LG CD4 CCL11
31 herpes zoster 29.7 DHFR CD8A CD40LG CD4
32 celiac disease 1 29.6 CD8A CD79A CD40LG CD4
33 pancytopenia 29.5 DHFR CSF3 CD8A CD40LG CD4
34 immunoglobulin alpha deficiency 29.5 MBL2 CD8A CD79A CD40LG CD4
35 bacterial infectious disease 29.2 MBL2 IL1A CSF3 CD8A CD40LG CD4
36 coccidiosis 29.2 HSPA4 DHFR CEMP1 CD8A CD40LG CD4
37 myeloma, multiple 29.0 HSPA4 CSF3 CD8A CD79A CD40LG CD4
38 parasitic protozoa infectious disease 29.0 TPI1 HSPA4 DHFR CXCL10 CD8A CD40LG
39 cholangitis, primary sclerosing 29.0 CD8A CD40LG CD4
40 inflammatory bowel disease 28.5 VIP TAC1 IL1A HSPA4 CXCL10 CD8A
41 malaria 27.7 TPI1 MBL2 IL1A HSPA4 DHFR CXCL10
42 cryptorchidism, unilateral or bilateral 11.3
43 acquired immunodeficiency syndrome 10.8
44 human immunodeficiency virus type 1 10.7
45 hemorrhagic fever-renal syndrome 10.6 CD79A CD40LG
46 c1q nephropathy 10.6 CD79A CD40LG
47 congenital rubella 10.6 CD40LG CAT
48 hilar lung carcinoma 10.6 CD79A CD40LG
49 lung hilum cancer 10.6 CD79A CD40LG
50 transient refractive change 10.6 TAC1 SST

Graphical network of the top 20 diseases related to Cryptosporidiosis:



Diseases related to Cryptosporidiosis

Symptoms & Phenotypes for Cryptosporidiosis

Human phenotypes related to Cryptosporidiosis:

58 31 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
2 decreased proportion of cd4-positive t cells 58 31 frequent (33%) Frequent (79-30%) HP:0005407
3 abnormal t cell count 58 31 frequent (33%) Frequent (79-30%) HP:0011839
4 failure to thrive 58 31 occasional (7.5%) Occasional (29-5%) HP:0001508
5 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
6 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
7 growth delay 58 31 occasional (7.5%) Occasional (29-5%) HP:0001510
8 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
9 chronic diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002028
10 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
11 low-grade fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0011134
12 intermittent diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002254
13 abdominal colic 58 31 occasional (7.5%) Occasional (29-5%) HP:0011848
14 dysphagia 58 31 very rare (1%) Very rare (<4-1%) HP:0002015
15 dehydration 58 31 very rare (1%) Very rare (<4-1%) HP:0001944
16 respiratory distress 58 31 very rare (1%) Very rare (<4-1%) HP:0002098
17 cough 58 31 very rare (1%) Very rare (<4-1%) HP:0012735
18 pancreatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001733
19 respiratory failure 58 31 very rare (1%) Very rare (<4-1%) HP:0002878
20 hypoxemia 58 31 very rare (1%) Very rare (<4-1%) HP:0012418
21 hoarse voice 58 31 very rare (1%) Very rare (<4-1%) HP:0001609
22 respiratory tract infection 58 31 very rare (1%) Very rare (<4-1%) HP:0011947
23 abnormal esophagus morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0002031
24 gastrointestinal obstruction 58 31 very rare (1%) Very rare (<4-1%) HP:0004796
25 cholangitis 58 31 very rare (1%) Very rare (<4-1%) HP:0030151
26 wheezing 58 31 very rare (1%) Very rare (<4-1%) HP:0030828
27 abdominal pain 58 Occasional (29-5%)
28 biliary tract abnormality 58 Very rare (<4-1%)
29 diarrhea 58 Frequent (79-30%)

UMLS symptoms related to Cryptosporidiosis:


fever, pruritus

MGI Mouse Phenotypes related to Cryptosporidiosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CACNA1B CCL11 CD4 CD40LG CD79A CD8A
2 immune system MP:0005387 9.47 CACNA1B CCL11 CD4 CD40LG CD79A CD8A

Drugs & Therapeutics for Cryptosporidiosis

Drugs for Cryptosporidiosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 3 83905-01-5 55185 447043
2
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490 46783538
5
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4 5360545
6
Ribavirin Approved Phase 2, Phase 3 36791-04-5 37542
7
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
8 Anti-Bacterial Agents Phase 3
9 Cytochrome P-450 Enzyme Inhibitors Phase 3
10 Antitubercular Agents Phase 3
11 Hormone Antagonists Phase 3
12 Antibiotics, Antitubercular Phase 3
13 Antifungal Agents Phase 3
14 Steroid Synthesis Inhibitors Phase 3
15 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
16 Hormones Phase 3
17 Liver Extracts Phase 2, Phase 3
18 Antiviral Agents Phase 2, Phase 3
19 Antimetabolites Phase 2, Phase 3
20 Anti-Infective Agents Phase 3
21 Antiparasitic Agents Phase 3
22 Antiprotozoal Agents Phase 3
23
Paromomycin Approved, Investigational Phase 1, Phase 2 7542-37-2, 1263-89-4 165580
24
Clofazimine Approved, Investigational Phase 2 2030-63-9 2794
25 Immunologic Factors Phase 1, Phase 2
26 Anti-Inflammatory Agents Phase 2
27 Angiogenesis Inhibitors Phase 1, Phase 2
28 Interleukin-12 Phase 1, Phase 2
29 Adjuvants, Immunologic Phase 1, Phase 2
30
Loperamide Approved Phase 1 53179-11-6 3955
31
Spiramycin Approved Phase 1 24916-50-5
32 Whey Protein Phase 1
33 Antibodies Phase 1
34 Immunoglobulins Phase 1
35 Antidiarrheals Phase 1
36 Vaccines Phase 1
37
Iodine Approved, Investigational 7553-56-2 807
38 Diclazuril Investigational, Vet_approved 101831-37-2
39 Immunoglobulins, Intravenous
40 Rho(D) Immune Globulin
41 gamma-Globulins
42 cadexomer iodine
43 Acidophilus

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
2 Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial Completed NCT01197157 Phase 2, Phase 3 Placebo;Nitazoxanide
3 Open Label, Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States Terminated NCT00004986 Phase 3 Nitazoxanide
4 A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Completed NCT00000771 Phase 2 Paromomycin sulfate
5 A Phase II/III Placebo-Controlled Study of Nitazoxanide (NTZ) For Persons With AIDS and Cryptosporidiosis Completed NCT00001081 Phase 2 Nitazoxanide
6 A Phase I/II Open Label Study of Nitazoxanide (NTZ) for the Treatment of Cryptosporidium Parvum in HIV Infected Infants, Children, and Adolescents Completed NCT00055107 Phase 1, Phase 2 Nitazoxanide
7 Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis Recruiting NCT02127398 Phase 2
8 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
9 A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS Terminated NCT00057486 Phase 1, Phase 2 IL-12
10 A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Completed NCT00002248 Phase 1 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
11 Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics and Dose Escalation, Efficacy, and Safety Study of Letrazuril for AIDS-Related Cryptosporidial Diarrhea Completed NCT00001018 Phase 1 Letrazuril
12 Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea Completed NCT00000980 Phase 1 Spiramycin
13 Phase I/II Open Label Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Completed NCT00002444 Phase 1 Nitazoxanide
14 Open-Label Compassionate Use of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Unknown status NCT00002158 Nitazoxanide
15 Parasitic Causes of Secretory Diarrhea in Children and Chronically Ill Adult. Unknown status NCT03166670
16 Efficacy of Cow's Milk Immune Globulin in the Treatment of Chronic Intestinal Cryptosporidiosis in Patients With AIDS Completed NCT00002264 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
17 Prevalence and Clinical Presentation of Respiratory Cryptosporidiosis Among Children With Diarrhea in Mulago Hospital, Uganda Completed NCT00507871
18 Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy Completed NCT00002328 Azithromycin
19 Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study Completed NCT00002082 Azithromycin
20 Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients Completed NCT00002062 Spiramycin
21 28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) Completed NCT00002278 Diclazuril
22 Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) Completed NCT00002027 Diclazuril
23 Pilot Intervention Trial of Ceramic Water Filters to Reduce the Burden of Cryptosporidium in Household Drinking Water in Rural Kenya. Completed NCT01695304
24 Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events Completed NCT01699841
25 Field Studies of Human Immunity to Amebiasis in Bangladesh: A Prospective Study of Children Ages 0-17 Years Completed NCT02734264
26 Diagnostics of Intestinal Parasitosis in Inhabitants of Kuyavian-Pomeranian Province in Poland Recruiting NCT03490435
27 Field Studies of Cryptosporidiosis and Enteropathogens in Bangladesh Active, not recruiting NCT02764918
28 Development of an Effective Treatment of Cryptosporidiosis in Bangladeshi Children Not yet recruiting NCT04103216
29 A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS Terminated NCT00001128 Interleukin-12;Paromomycin sulfate;Azithromycin
30 Study of Patients With Parasitic Infections of the Gastrointestinal Tract Terminated NCT00001162

Search NIH Clinical Center for Cryptosporidiosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


nitazoxanide

Cochrane evidence based reviews: cryptosporidiosis

Genetic Tests for Cryptosporidiosis

Anatomical Context for Cryptosporidiosis

MalaCards organs/tissues related to Cryptosporidiosis:

40
Lung, Small Intestine, T Cells, Testes, Liver, Colon, B Cells

Publications for Cryptosporidiosis

Articles related to Cryptosporidiosis:

(show top 50) (show all 3345)
# Title Authors PMID Year
1
Bovine Cryptosporidium parvum field isolates differ in cytopathogenicity in HCT-8 monolayers. 61 42
31442896 2019
2
Epidemiologic Surveillance in Israel of Cryptosporidium, a Unique Waterborne Notifiable Pathogen, and Public Health Policy. 61 42
31542902 2019
3
Molecular identification of Cryptosporidium parvum in rabbits (Oryctolagus cuniculus) in Nigeria 42
31599539 2019
4
Association of mannose-binding lectin deficiency with cryptosporidiosis. 54 61
16804842 2006
5
Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children. 54 61
16804841 2006
6
Targeting DHFR in parasitic protozoa. 54 61
15718161 2005
7
Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS. 54 61
11054381 2000
8
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. 54 61
8855552 1996
9
From mice to men: Three cases of human infection with Cryptosporidium ditrichi. 61
31751756 2020
10
Cryptosporidium Infection Increases the Risk for Chronic Diarrhea Among People Living With HIV in Southeast Asia: A Systematic Review and Meta-Analysis. 61
32037854 2020
11
Genome-Wide Association Study of Cryptosporidiosis in Infants Implicates PRKCA. 61
32019797 2020
12
Surface waters as a potential source of Giardia and Cryptosporidium in Serbia. 61
31870927 2020
13
Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp. 61
31885132 2020
14
Correlates of pathological lesions associated with respiratory cryptosporidiosis prevalence in shot red grouse Lagopus lagopus scotica from moors in northern England. 61
31545656 2020
15
Association between Cryptosporidium infection and cancer: A systematic review and meta-analysis. 61
31472267 2020
16
Evaluation of the effects of anthelmintic administration on the fecal microbiome of healthy dogs with and without subclinical Giardia spp. and Cryptosporidium canis infections. 61
32027665 2020
17
Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics. 61
31452167 2020
18
Cryptosporidium parvum as a risk factor of diarrhea occurrence in neonatal alpacas in Peru. 61
31754858 2020
19
Cryptosporidiosis. 61
31961421 2020
20
A One Health Approach to Tackle Cryptosporidiosis. 61
31983609 2020
21
First report of zoonotic Cryptosporidium parvum GP60 subtypes IIaA15G2R1 and IIaA16G3R1 in wild ponies from the northern Iberian Peninsula. 61
31758296 2020
22
Occurrence and genetic characteristics of Cryptosporidium spp. and Enterocytozoon bieneusi in pet red squirrels (Sciurus vulgaris) in China. 61
31974403 2020
23
Molecular study and genotyping of Cryptosporidium baileyi and Cryptosporidium parvum from free-range and commercial broiler chickens in Guilan province, Iran. 61
31951878 2020
24
Fecal Immunoglobulin A Against a Sporozoite Antigen at 12 Months Is Associated With Delayed Time to Subsequent Cryptosporidiosis in Urban Bangladesh: A Prospective Cohort Study. 61
31131855 2020
25
Mouse Models for Use in Cryptosporidium Infection Studies and Quantification of Parasite Burden Using Flow Cytometry, qPCR, and Histopathology. 61
31452166 2020
26
An immunocompetent rat model of infection with Cryptosporidium hominis and Cryptosporidium parvum. 61
31759945 2020
27
Cryptosporidium Diagnostic Assays: Microscopy. 61
31452153 2020
28
Cryptosporidium Diagnostic Assays: Molecular Detection. 61
31452154 2020
29
Production and Purification of Functional Cryptosporidium Glycoproteins by Heterologous Expression in Toxoplasma gondii. 61
31452158 2020
30
A Novel Method to Silence Genes in Cryptosporidium. 61
31452163 2020
31
Development of a gp60-subtyping method for Cryptosporidium felis. 61
31973771 2020
32
Cryptosporidium Oocyst Purification Using Discontinuous Gradient Centrifugation. 61
31452156 2020
33
High-Content Screening for Cryptosporidium Drug Discovery. 61
31452169 2020
34
Decreased SLC26A3 expression and function in intestinal epithelial cells in response to Cryptosporidium parvum infection. 61
31483700 2019
35
Projected local rain events due to climate change and the impacts on waterborne diseases in Vancouver, British Columbia, Canada. 61
31888648 2019
36
Prevalence and molecular characterization of Cryptosporidium spp. and Giardia intestinalis in household dogs and cats from Shiraz, Southwestern Iran. 61
31955553 2019
37
Comparative genomics: how has it advanced our knowledge of cryptosporidiosis epidemiology? 61
31724068 2019
38
Cryptosporidium Infection: Epidemiology, Pathogenesis, and Differential Diagnosis. 61
31934363 2019
39
Anti-protozoal activity of extracts from chicory (Cichorium intybus) against Cryptosporidium parvum in cell culture. 61
31892721 2019
40
Structure activity relationship towards design of cryptosporidium specific thymidylate synthase inhibitors. 61
31536894 2019
41
Cryptosporidium parvum elongation factor 1α (CpEF1α) participates in the formation of base structure at the infection site during invasion. 61
31872225 2019
42
Development of a real-time PCR assay for detection of Cryptosporidium canis in dog fecal samples. 61
31796184 2019
43
Molecular characterization of Cryptosporidium isolates from diarrheal dairy calves in France. 61
31796198 2019
44
Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening. 61
30451014 2019
45
Performance of three rapid diagnostic tests for the detection of Cryptosporidium spp. and Giardia duodenalis in children with severe acute malnutrition and diarrhoea. 61
31775877 2019
46
Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection. 61
31694928 2019
47
Exploring the geographical distribution of cryptosporidiosis in the cattle population of Southern Ontario, Canada, 2011-2014. 61
31724373 2019
48
Identification of adaptive inhibitors of Cryptosporidium parvum fatty acyl-coenzyme A synthetase isoforms by virtual screening. 61
31486948 2019
49
Austwickiosis in Captive African Spurred Tortoises (Geochelone sulcata) Co-infected with Cryptosporidium ducismarci. 61
31812167 2019
50
[A Rare Complication of Acute Diarrhae Caused by Cryptosporidium: Possible Hepatobiliary System Involvement in a Child without Immunodeficiency]. 61
31709944 2019

Variations for Cryptosporidiosis

Expression for Cryptosporidiosis

Search GEO for disease gene expression data for Cryptosporidiosis.

Pathways for Cryptosporidiosis

GO Terms for Cryptosporidiosis

Cellular components related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VIP TAC1 SST MBL2 IL1A CXCL10
2 external side of plasma membrane GO:0009897 9.55 CXCL10 CD8A CD79A CD40LG CD4
3 extracellular space GO:0005615 9.32 TPI1 TAC1 SST MBL2 IL1A CXCL10

Biological processes related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.65 TAC1 IL1A CXCL10 CD40LG CCL11
2 cytokine-mediated signaling pathway GO:0019221 9.55 IL1A CXCL10 CSF3 CD4 CCL11
3 neutrophil chemotaxis GO:0030593 9.5 IL1A CXCL10 CCL11
4 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.37 IL1A CD4
5 cell surface receptor signaling pathway GO:0007166 9.35 SST CXCL10 CD8A CD79A CD4
6 immune response GO:0006955 9.17 IL1A CXCL10 CSF3 CD8A CD40LG CD4

Molecular functions related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL1A CXCL10 CSF3 CD40LG CCL11

Sources for Cryptosporidiosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....